A citation-based method for searching scientific literature


List of co-cited articles
88 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
75

A mouse model for EML4-ALK-positive lung cancer.
Manabu Soda, Shuji Takada, Kengo Takeuchi, Young Lim Choi, Munehiro Enomoto, Toshihide Ueno, Hidenori Haruta, Toru Hamada, Yoshihiro Yamashita, Yuichi Ishikawa,[...]. Proc Natl Acad Sci U S A 2008
378
50

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
50

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Robert C Doebele, Amanda B Pilling, Dara L Aisner, Tatiana G Kutateladze, Anh T Le, Andrew J Weickhardt, Kimi L Kondo, Derek J Linderman, Lynn E Heasley, Wilbur A Franklin,[...]. Clin Cancer Res 2012
765
41

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
Young Lim Choi, Manabu Soda, Yoshihiro Yamashita, Toshihide Ueno, Junpei Takashima, Takahiro Nakajima, Yasushi Yatabe, Kengo Takeuchi, Toru Hamada, Hidenori Haruta,[...]. N Engl J Med 2010
840
41

The biology and treatment of EML4-ALK non-small cell lung cancer.
Takaaki Sasaki, Scott J Rodig, Lucian R Chirieac, Pasi A Jänne. Eur J Cancer 2010
361
41

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Ryohei Katayama, Alice T Shaw, Tahsin M Khan, Mari Mino-Kenudson, Benjamin J Solomon, Balazs Halmos, Nicholas A Jessop, John C Wain, Alan Tien Yeo, Cyril Benes,[...]. Sci Transl Med 2012
876
41

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall,[...]. N Engl J Med 2013
41

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
41

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
Takaaki Sasaki, Jussi Koivunen, Atsuko Ogino, Masahiko Yanagita, Sarah Nikiforow, Wei Zheng, Christopher Lathan, J Paul Marcoux, Jinyan Du, Katsuhiro Okuda,[...]. Cancer Res 2011
435
33

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima, Tatsushi Kodama, Takamitsu Kobayashi, Takaaki A Fukami, Nobuhiro Oikawa, Takuo Tsukuda, Nobuya Ishii, Yuko Aoki. Cancer Cell 2011
422
33

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
Young Lim Choi, Kengo Takeuchi, Manabu Soda, Kentaro Inamura, Yuki Togashi, Satoko Hatano, Munehiro Enomoto, Toru Hamada, Hidenori Haruta, Hideki Watanabe,[...]. Cancer Res 2008
324
33

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
33

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
33

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
Jussi P Koivunen, Craig Mermel, Kreshnik Zejnullahu, Carly Murphy, Eugene Lifshits, Alison J Holmes, Hwan Geun Choi, Jhingook Kim, Derek Chiang, Roman Thomas,[...]. Clin Cancer Res 2008
705
25

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
James G Christensen, Helen Y Zou, Maria E Arango, Qiuhua Li, Joseph H Lee, Scott R McDonnell, Shinji Yamazaki, Gordon R Alton, Barbara Mroczkowski, Gerrit Los. Mol Cancer Ther 2007
491
25

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.
Lecia V Sequist, Scott Gettinger, Neil N Senzer, Renato G Martins, Pasi A Jänne, Rogerio Lilenbaum, Jhanelle E Gray, A John Iafrate, Ryohei Katayama, Nafeeza Hafeez,[...]. J Clin Oncol 2010
263
25

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
Ryohei Katayama, Tahsin M Khan, Cyril Benes, Eugene Lifshits, Hiromichi Ebi, Victor M Rivera, William C Shakespeare, A John Iafrate, Jeffrey A Engelman, Alice T Shaw. Proc Natl Acad Sci U S A 2011
399
25

Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
Ken Takezawa, Isamu Okamoto, Kazuto Nishio, Pasi A Jänne, Kazuhiko Nakagawa. Clin Cancer Res 2011
103
25

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
S W Morris, M N Kirstein, M B Valentine, K G Dittmer, D N Shapiro, D L Saltman, A T Look. Science 1994
25


ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Giorgio Scagliotti, Rolf A Stahel, Rafael Rosell, Nick Thatcher, Jean-Charles Soria. Eur J Cancer 2012
60
25

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.
Kengo Takeuchi, Young Lim Choi, Yuki Togashi, Manabu Soda, Satoko Hatano, Kentaro Inamura, Shuji Takada, Toshihide Ueno, Yoshihiro Yamashita, Yukitoshi Satoh,[...]. Clin Cancer Res 2009
518
25


Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima,[...]. Lancet Oncol 2010
25

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita,[...]. N Engl J Med 2010
25

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, Sheheryar Kabraji, Mark M Awad, Ryohei Katayama, Amanda Pawlak, Mari Mino-Kenudson, Beow Y Yeap, Gregory J Riely,[...]. Clin Cancer Res 2013
361
25

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Luc Friboulet, Nanxin Li, Ryohei Katayama, Christian C Lee, Justin F Gainor, Adam S Crystal, Pierre-Yves Michellys, Mark M Awad, Noriko Yanagitani, Sungjoon Kim,[...]. Cancer Discov 2014
527
25

Ceritinib in ALK-rearranged non-small-cell lung cancer.
Alice T Shaw, Dong-Wan Kim, Ranee Mehra, Daniel S W Tan, Enriqueta Felip, Laura Q M Chow, D Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas,[...]. N Engl J Med 2014
998
25

Crizotinib in the treatment of non--small-cell lung cancer.
Sacha I Rothschild, Oliver Gautschi. Clin Lung Cancer 2013
27
25

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.
T Iwahara, J Fujimoto, D Wen, R Cupples, N Bucay, T Arakawa, S Mori, B Ratzkin, T Yamamoto. Oncogene 1997
476
25

New strategies for treatment of ALK-rearranged non-small cell lung cancers.
Takaaki Sasaki, Pasi A Jänne. Clin Cancer Res 2011
54
16

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
Ultan McDermott, A John Iafrate, Nathanael S Gray, Toshi Shioda, Marie Classon, Shyamala Maheswaran, Wenjun Zhou, Hwan Geun Choi, Shannon L Smith, Lori Dowell,[...]. Cancer Res 2008
322
16

Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.
Sen Zhang, Frank Wang, Jeffrey Keats, Xiaotian Zhu, Yaoyu Ning, Scott D Wardwell, Lauren Moran, Qurish K Mohemmad, Rana Anjum, Yihan Wang,[...]. Chem Biol Drug Des 2011
106
16

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
Johannes M Heuckmann, Hyatt Balke-Want, Florian Malchers, Martin Peifer, Martin L Sos, Mirjam Koker, Lydia Meder, Christine M Lovly, Lukas C Heukamp, William Pao,[...]. Clin Cancer Res 2012
180
16

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
Takaaki Sasaki, Katsuhiro Okuda, Wei Zheng, James Butrynski, Marzia Capelletti, Liping Wang, Nathanael S Gray, Keith Wilner, James G Christensen, George Demetri,[...]. Cancer Res 2010
241
16

Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
Heae Surng Park, June Koo Lee, Dong-Wan Kim, Kimary Kulig, Tae Min Kim, Se-Hoon Lee, Yoon-Kyung Jeon, Doo Hyun Chung, Dae Seog Heo. Lung Cancer 2012
93
16

Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.
Eunhee S Yi, Jennifer M Boland, Joseph J Maleszewski, Anja C Roden, Andre M Oliveira, Marie-Christine Aubry, Michele R Erickson-Johnson, Bolette L Caron, Yan Li, Hui Tang,[...]. J Thorac Oncol 2011
219
16

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.
Mari Mino-Kenudson, Lucian R Chirieac, Kenny Law, Jason L Hornick, Neal Lindeman, Eugene J Mark, David W Cohen, Bruce E Johnson, Pasi A Jänne, A John Iafrate,[...]. Clin Cancer Res 2010
340
16

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
Daniel B Costa, Susumu Kobayashi, Shuchi S Pandya, Wee-Lee Yeo, Zhongzhou Shen, Weiwei Tan, Keith D Wilner. J Clin Oncol 2011
430
16


Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Lecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B Turke, Panos Fidias, Kristin Bergethon, Alice T Shaw, Scott Gettinger, Arjola K Cosper,[...]. Sci Transl Med 2011
16

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
Takashi Seto, Katsuyuki Kiura, Makoto Nishio, Kazuhiko Nakagawa, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Nobuyuki Yamamoto, Hiroshige Yoshioka, Masao Harada,[...]. Lancet Oncol 2013
418
16

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Alice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy, Daniel B Costa, Rebecca S Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott,[...]. J Clin Oncol 2009
16

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
Johannes M Heuckmann, Michael Hölzel, Martin L Sos, Stefanie Heynck, Hyatt Balke-Want, Mirjam Koker, Martin Peifer, Jonathan Weiss, Christine M Lovly, Christian Grütter,[...]. Clin Cancer Res 2011
132
16

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D Ross Camidge, Yung-Jue Bang, Eunice L Kwak, A John Iafrate, Marileila Varella-Garcia, Stephen B Fox, Gregory J Riely, Benjamin Solomon, Sai-Hong I Ou, Dong-Wan Kim,[...]. Lancet Oncol 2012
891
16

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Helena A Yu, Maria E Arcila, Natasha Rekhtman, Camelia S Sima, Maureen F Zakowski, William Pao, Mark G Kris, Vincent A Miller, Marc Ladanyi, Gregory J Riely. Clin Cancer Res 2013
16

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
William Pao, Vincent Miller, Maureen Zakowski, Jennifer Doherty, Katerina Politi, Inderpal Sarkaria, Bhuvanesh Singh, Robert Heelan, Valerie Rusch, Lucinda Fulton,[...]. Proc Natl Acad Sci U S A 2004
16

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.
K Azuma, K Ota, A Kawahara, S Hattori, E Iwama, T Harada, K Matsumoto, K Takayama, S Takamori, M Kage,[...]. Ann Oncol 2014
418
16



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.